UBS AM’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$6.5B Buy
7,072,021
+572,691
+9% +$581M 1.35% 10
2025
Q4
$6.98B Buy
6,499,330
+66,373
+1% +$63.5M 1.48% 10
2025
Q3
$4.91B Sell
6,432,957
-1,438,524
-18% -$1.07B 1.07% 11
2025
Q2
$6.14B Buy
7,871,481
+1,093,890
+16% +$850M 1.24% 9
2025
Q1
$5.6B Sell
6,777,591
-307,289
-4% -$256M 1.43% 7
2024
Q4
$5.47B Buy
7,084,880
+969,376
+16% +$803M 1.28% 10
2024
Q3
$5.42B Buy
6,115,504
+157,741
+3% +$142M 1.39% 10
2024
Q2
$5.39B Buy
5,957,763
+1,337,908
+29% +$1.07B 1.55% 8
2024
Q1
$3.59B Buy
4,619,855
+121,525
+3% +$86.5M 1.28% 9
2023
Q4
$2.62B Buy
4,498,330
+125,548
+3% +$73.3M 1.03% 12
2023
Q3
$2.35B Sell
4,372,782
-247,830
-5% -$128M 1.05% 10
2023
Q2
$1.59B Hold
4,620,612
0.77% 17
2023
Q1
$1.59B Buy
4,620,612
+340,500
+8% +$115M 0.77% 17
2022
Q4
$1.57B Buy
4,280,112
+294,554
+7% +$104M 0.82% 14
2022
Q3
$1.29B Sell
3,985,558
-201,487
-5% -$63.8M 0.72% 18
2022
Q2
$1.36B Sell
4,187,045
-217,589
-5% -$65.3M 0.71% 19
2022
Q1
$1.26B Buy
4,404,634
+35,764
+0.8% +$9.2M 0.54% 26
2021
Q4
$1.21B Sell
4,368,870
-137,698
-3% -$34.9M 0.46% 33
2021
Q3
$1.04B Sell
4,506,568
-152,747
-3% -$37.7M 0.43% 39
2021
Q2
$1.07B Buy
4,659,315
+275,432
+6% +$55.3M 0.46% 34
2021
Q1
$819M Buy
4,383,883
+117,056
+3% +$22.9M 0.36% 51
2020
Q4
$720M Sell
4,266,827
-161,306
-4% -$24.1M 0.34% 54
2020
Q3
$655M Buy
4,428,133
+83,647
+2% +$12.9M 0.35% 52
2020
Q2
$713M Sell
4,344,486
-157,806
-4% -$24.2M 0.44% 40
2020
Q1
$625M Buy
4,502,292
+210,040
+5% +$28.9M 0.45% 39
2019
Q4
$564M Buy
4,292,252
+42,232
+1% +$4.9M 0.35% 55
2019
Q3
$475M Buy
4,250,020
+82,971
+2% +$9.24M 0.32% 62
2019
Q2
$462M Buy
4,167,049
+197,542
+5% +$23.3M 0.33% 59
2019
Q1
$515M Sell
3,969,507
-1,012,937
-20% -$123M 0.38% 51
2018
Q4
$577M Buy
4,982,444
+259,244
+5% +$29M 0.5% 35
2018
Q3
$507M Sell
4,723,200
-123,864
-3% -$12.4M 0.38% 51
2018
Q2
$414M Buy
4,847,064
+80,091
+2% +$6.58M 0.32% 59
2018
Q1
$369M Sell
4,766,973
-1,869,413
-28% -$150M 0.29% 70
2017
Q4
$561M Buy
6,636,386
+115,499
+2% +$9.83M 0.48% 35
2017
Q3
$558M Buy
6,520,887
+283,499
+5% +$23.3M 0.51% 37
2017
Q2
$513M Sell
6,237,388
-651,575
-9% -$53.2M 0.5% 38
2017
Q1
$579M Buy
6,888,963
+482,576
+8% +$38.7M 0.59% 33
2016
Q4
$471M Buy
6,406,387
+1,195,661
+23% +$89M 0.53% 33
2016
Q3
$418M Sell
5,210,726
-172,153
-3% -$13.8M 0.45% 46
2016
Q2
$424M Buy
5,382,879
+84,469
+2% +$6.36M 0.48% 43
2016
Q1
$382M Buy
5,298,410
+434,765
+9% +$32.9M 0.44% 45
2015
Q4
$410M Sell
4,863,645
-316,016
-6% -$26.2M 0.47% 42
2015
Q3
$433M Buy
5,179,661
+209,321
+4% +$17.7M 0.48% 41
2015
Q2
$415M Sell
4,970,340
-607,423
-11% -$46.3M 0.4% 51
2015
Q1
$405M Sell
5,577,763
-155,896
-3% -$11.1M 0.39% 54
2014
Q4
$396M Sell
5,733,659
-369,298
-6% -$24.9M 0.38% 55
2014
Q3
$396M Sell
6,102,957
-321,487
-5% -$20.4M 0.39% 57
2014
Q2
$399M Sell
6,424,444
-209,984
-3% -$12.5M 0.4% 57
2014
Q1
$391M Buy
6,634,428
+108,854
+2% +$6.08M 0.42% 54
2013
Q4
$333M Buy
6,525,574
+471,129
+8% +$23.6M 0.38% 56
2013
Q3
$305M Buy
6,054,445
+1,290,745
+27% +$67.6M 0.38% 59
2013
Q2
$234M Buy
+4,763,700
New +$259M 0.3% 82

Other funds holding LLY

UBS AM's LLY Position: Q1 2026 in Review

UBS AM increased its Eli Lilly (LLY) stake by 8.8% in Q1 2026, buying an estimated $581M and bringing the position to 7,072,021 shares worth $6.5B. The position accounts for 1.35% of the portfolio, ranked #10.

UBS AM first reported a position in LLY in Q2 2013 and has held it in 52 quarters since. The position peaked at $6.98B in Q4 2025. 4,354 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • UBS AM held 7,072,021 shares of Eli Lilly worth $6.5B as of Q1 2026.
  • UBS AM bought 572,691 Eli Lilly shares in Q1 2026, an estimated $581M.
  • Eli Lilly made up 1.35% of UBS AM's portfolio in Q1 2026, its #10 holding.
  • UBS AM first reported a position in Eli Lilly in Q2 2013 and has held it in 52 quarters since.
  • UBS AM's Eli Lilly position peaked at $6.98B in Q4 2025.
  • 4,354 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on UBS AM's 13F filing for Q1 2026, filed 13 May 2026.